Chargement en cours...
Emerging novel therapies in the treatment of castrate-resistant prostate cancer
The treatment options for patients with castration-resistant prostate cancer (CRPC), until very recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration (FDA) approved agents in the United States have shown survival benefit for patients with CRPC. This review takes...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Canadian Medical Association
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3104424/ https://ncbi.nlm.nih.gov/pubmed/21470540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.10160 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|